SOMAÍ Pharmaceuticals

SOMAÍ Pharmaceuticals Somai is fast becoming one of the most recognized and well-developed pharmaceutical brands in the EU.

A leading EU-GMP European vertically integrated Multi-Country Operator (MCO) company with a global footprint of distribution for the largest and most advanced EU GMP-certified cannabinoid-containing pharmaceutical extract portfolio Somai Pharmaceuticals LTD is a European pharmaceutical and biotech company centered on manufacturing in Lisbon, Portugal and distribution of EU GMP-certified cannabinoi

d-containing pharmaceuticals throughout the European Union and globally. Somai emphasizes scientific pharmacology applications with EU-GMP standards to deliver treatments to the endocannabinoid system, effectively and with consistency across all markets. Somai's product development knowledge was honed in the competitive American market, and is the largest and most advanced cannabinoid manufacturing facility across legal European markets producing medicines products and registered API's. Somai has brought together an all-star team of scientists and KOL's from around the world with various clinical experiences to guide Somai's product development and acceptance globally. Somai stresses education and continual R&D, which started from the USA as transformative developments, to help EU doctors and patients properly diagnose and treat the individual indications by providing variable dosage choices. Somai’s primary goal is producing the most advanced products with the most innovative delivery methods to create maximum bioavailability and healing for patients. As a global biotech player concentrating on cannabinoids, Somai has a unique pipeline of current and future products that will be on the market starting in late 2022. They already boast one of the largest IP (Intellectual Property) vaults of APIs that weren’t accessible to Europe until recently. Somai’s near term products conform to the highest standards of herbal medicine (ACM) and specialized cannabinoid API’s for R&D, but also keeps a steady eye on the horizon of future clinical trials for their proprietary pipeline, setting it up to be well positioned for the next decade.

28/04/2026

Inside SOMAÍ Cultivation with Dr. Nigel Gale 🔹

Why do we take cuttings from the very top of the plant?

This is where plant science, consistency, and careful cultivation practice come together. In this episode, Dr. Nigel Gale explains how top cuttings support the development of strong new plants, helping preserve the genetic blueprint and quality potential of each cultivar.

At SOMAÍ and NovaSoma, every step in cultivation is guided by precision, care, and a deep understanding of the plant.

More from our cultivation series coming soon. 💙

CannabisScience CultivationExcellence MedicalCannabisEducation

28/04/2026

Inside SOMAÍ Cultivation with Dr. Nigel Gale 🔹

Why do we take cuttings from the very top of the plant?

Because this is where plant science, consistency, and careful cultivation practice come together. In this episode, Dr. Nigel Gale explains how top cuttings support the development of strong new plants, helping preserve the genetic blueprint and quality potential of each cultivar.

At SOMAÍ and NovaSoma, every step in cultivation is guided by precision, care, and a deep understanding of the plant.

More from our cultivation series coming soon. 💙

For two decades, the fight to acknowledge cannabis as a legitimate medicine in the USA has stumbled through a lobbying a...
27/04/2026

For two decades, the fight to acknowledge cannabis as a legitimate medicine in the USA has stumbled through a lobbying and bureaucratic minefield. But the landscape has shifted permanently. While recent Trump executive actions don’t fully “legalize” the plant recreationally, they send a thunderous message: the FDA will officially acknowledge cannabis as a medicine.

As regulatory frameworks evolve across multiple markets, companies are being pushed to operate with the same rigor as traditional pharmaceutical systems — from cultivation through to final product release.

A new article by Michael Sassano published in Ignite IT highlights a key shift in the industry: the move toward EU-GMP-driven medical cannabis supply chains and global standardisation.

Explore the full article and key insights: https://www.igniteit.com/news/boom-the-age-of-eu-gmp-medical-cannabis-is-here-the-global-race-is-on/

23/04/2026

🔵 ICBC 2026 — Thank You 🌐

Thank you to everyone who connected with the SOMAÍ team at .

From insightful conversations to new partnerships, it was a great few days discussing the future of medical cannabis.

We look forward to continuing the conversations — see you next year.

23/04/2026

🔵 ICBC 2026 — Thank You 🌐

Thank you to everyone who connected with the SOMAÍ team at International Cannabis Business Conference Berlin.

From insightful conversations to new partnerships, it was a great few days discussing the future of medical cannabis.

We look forward to continuing the conversations — see you next year.

SOMAÍ today announced a manufacturing partnership with Bedrocan, a leading international manufacturer of pharmaceutical-...
21/04/2026

SOMAÍ today announced a manufacturing partnership with Bedrocan, a leading international manufacturer of pharmaceutical-grade medicinal cannabis.

Under the agreement, Bedrocan will supply its cannabis flower, which SOMAÍ will process into EU-GMP-compliant oral solutions and potentially other extract-based formulations. These products will be developed and commercialized under the Bedrocan brand across international medical cannabis markets.

The partnership reflects a shared focus on standardization, quality, and regulatory compliance across the medical cannabis value chain. “Bedrocan has established a global reputation for standardizing its production methods and assuring pharmaceutical-grade cannabis with consistent cannabinoid composition,” said George Bellow, Co-Founder of SOMAÍ. “Our role is to translate that consistency into EU-GMP extract formulations that meet the expectations of healthcare professionals and international medical markets.” By combining Bedrocan’s cannabis as an active pharmaceutical ingredient with SOMAÍ’s EU-GMP manufacturing and formulation capabilities, the collaboration supports the development of cannabis-based medicines with reliable dosing, reproducible therapeutic profiles, and consistent patient outcomes.

"SOMAÍ's proven quality standards and expertise in cannabinoid formulation and manufacturing have been key to establishing this relationship. Their rigorous approach to quality and control has been fundamental to how we've been able to manufacture and develop new Bedrocan products," said Jaap Erkelens, CEO of Bedrocan International.

Read the full news here: https://www.einpresswire.com/article/907003308/soma-to-develop-bedrocan-eu-gmp-cannabis-extracts-for-global-medical-markets

20/04/2026

This 4/20, we’re reflecting on what matters most.

People care about results.
About feeling better.
About being heard, supported, and cared for.

Thank you to everyone who has shared their experience with SOMAÍ. Your trust means everything to us. 💙

#420

____
Background voice by Brian Tracy

20/04/2026

This 4/20, we’re reflecting on what matters most.

People care about results.
About feeling better.
About being heard, supported, and cared for.

Thank you to everyone who has shared their experience with SOMAÍ. Your trust means everything to us. 💙

#420

________
Background voice by Brian Tracy

🔵 SOMAÍ at Business of Cannabis Awards 2026 🌐We’re pleased to share that Michael Sassano, Founder and Interim CEO of SOM...
16/04/2026

🔵 SOMAÍ at Business of Cannabis Awards 2026 🌐

We’re pleased to share that Michael Sassano, Founder and Interim CEO of SOMAÍ, will serve as a judge at the Business of Cannabis Awards 2026.

This follows Michael being named Business Leader of the Year at the 2025 Business of Cannabis Awards, recognizing his leadership and contribution to the development of the global medical cannabis industry.

As the sector continues to evolve, initiatives like these play an important role in highlighting innovation, operational excellence, and leadership across international markets.

We look forward to celebrating this year’s nominees and the continued progress of the industry.

Learn more: https://businessofcannabis.com/awards/

SOMAÍ will be attending LogiPharma | 14–16 April in Vienna, joining global pharmaceutical leaders to discuss supply chai...
10/04/2026

SOMAÍ will be attending LogiPharma | 14–16 April in Vienna, joining global pharmaceutical leaders to discuss supply chain excellence and operational strategy.

🔷 On Day 3 | 16 April at 13:50, George Bellow, Co-Founder of SOMAÍ, will present a case study:
“Rapidly Scaling Cannabis Operations Worldwide: How to apply pharmaceutical discipline and regulatory agility without losing control – lessons learned for every supply chain.”

🔷 The session will explore how cannabis operations can scale globally while maintaining EU-GMP standards, regulatory compliance, and supply chain integrity.

We look forward to engaging with industry peers and sharing insights on building resilient, compliant global supply chains.

Portugal has long been the pioneer and undisputed leader in the EU cannabis markets. We are home to the biggest names in...
10/04/2026

Portugal has long been the pioneer and undisputed leader in the EU cannabis markets. We are home to the biggest names in the game — Curaleaf, Tilray, SOMAÍ — plus 65 other groups, with more on the way. The reason for this dominance is clear: excellence in pharmaceutical regulations. Portuguese regulators have been the gold standard, understanding cannabis exports and pharmaceutical distribution better than almost anyone globally.

Explore Michael Sassano's article in CannaReporter: https://cannareporter.eu/en/2026/03/13/Portugal-is-the-leader-in-the-European-Union-in-the-cannabis-market--but-this-leadership-is-threatened./

George Bellow, CO-Founder of SOMAI, will be speaking at Talman House Berlin on 13 April 2026 as part of the panel:Buyer ...
09/04/2026

George Bellow, CO-Founder of SOMAI, will be speaking at Talman House Berlin on 13 April 2026 as part of the panel:

Buyer Beware: Navigating Pitfalls in Global Cannabis Investments

As the global cannabis industry continues to evolve, so do the risks and realities facing investors, operators, and stakeholders. This panel will explore the challenges shaping international cannabis investing — from regulatory volatility and price compression to compliance costs, export limitations, and shifting political sentiment.

It will be a timely conversation on how to assess opportunities more carefully, mitigate risk, and build resilient strategies in an increasingly complex global market.

If you’re attending Talman House Berlin, don’t miss the discussion.

Address

Brisbane, QLD

Website

Alerts

Be the first to know and let us send you an email when SOMAÍ Pharmaceuticals posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to SOMAÍ Pharmaceuticals:

Shortcuts

Featured

Share

Category